Literature DB >> 20594582

Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma.

José García-Solano1, Miguel Pérez-Guillermo, Pablo Conesa-Zamora, Jesús Acosta-Ortega, Javier Trujillo-Santos, Pablo Cerezuela-Fuentes, Markus J Mäkinen.   

Abstract

Colorectal serrated adenocarcinoma represents a subtype of colorectal carcinoma that originates from serrated adenomas. Previous studies have suggested a more aggressive course, but this has not been verified. The aim of this work was to test the diagnostic reproducibility of previously proposed histologic criteria for serrated adenocarcinoma and to analyze the clinicopathologic features and outcome that would warrant its recognition as a new subtype of colorectal cancer. Nine hundred twenty-seven consecutive colorectal cancer specimens were used to search for cases fulfilling the criteria of serrated adenocarcinoma and matched controls. Clinicopathologic findings of 85 serrated adenocarcinomas were compared with a matched control group of conventional cancers. Serrated adenocarcinomas were encountered in 9.1% (n = 85) of cases. Residual serrated adenoma was present in 44 (51.7%). Absence of residual adenoma did not have any influence on the parameters studied. Interobserver variation between 2 Spanish and a Finnish pathologist showed moderate agreement (κ = .5873). Compared with their matched controls, serrated adenocarcinomas were more often accompanied by synchronous residual serrated adenomas (P < .0001), remote serrated adenomas (P = .0035), and serrated adenocarcinomas or cancers representing partial features of these tumors (P = .002). They had a less favorable 5-year survival than conventional cancers (P = .048 Breslow, Kaplan-Meier), and left-sided ones had the worst prognosis (P = .001). Serrated adenocarcinoma is an identifiable subset of colorectal cancer; and the histopathologic differences, in addition to its less favorable prognosis, may justify its recognition as a distinct subset of colorectal cancer warranting the search for specific clinical management strategies.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20594582     DOI: 10.1016/j.humpath.2010.04.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  38 in total

1.  Annexin A10 is a marker for the serrated pathway of colorectal carcinoma.

Authors:  Sara A Sajanti; Juha P Väyrynen; Päivi Sirniö; Kai Klintrup; Jyrki Mäkelä; Anne Tuomisto; Markus J Mäkinen
Journal:  Virchows Arch       Date:  2014-11-14       Impact factor: 4.064

Review 2.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 3.  Serrated pathway: alternative route to colorectal cancer.

Authors:  Arpád V Patai; Béla Molnár; Zsolt Tulassay; Ferenc Sipos
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

Review 4.  Serrated polyps and the risk of synchronous colorectal advanced neoplasia: a systematic review and meta-analysis.

Authors:  Qinyan Gao; Kelvin K F Tsoi; Hoyee W Hirai; Martin C S Wong; Francis K L Chan; Justin C Y Wu; James Y W Lau; Joseph J Y Sung; Siew C Ng
Journal:  Am J Gastroenterol       Date:  2015-03-10       Impact factor: 10.864

5.  Histology subtypes and polyp size are associated with synchronous colorectal carcinoma of colorectal serrated polyps: a study of 499 serrated polyps.

Authors:  Hailong Zhu; Guofeng Zhang; Xianghua Yi; Xuyou Zhu; Yunjin Wu; Jun Liang; Suxia Zhang; Yu Zeng; Desheng Fan; Xiaoting Yu; Jian He; Guozhong He; Zheng Chen; Shengzhong Duan; Lanjing Zhang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

6.  Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma.

Authors:  Hailong Zhu; Huali Qin; Ziling Huang; Shuai Li; Xuyou Zhu; Jian He; Jing Yang; Xiaoting Yu; Xianghua Yi
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

7.  Comparison of allelic discrimination by dHPLC, HRM, and TaqMan in the detection of BRAF mutation V600E.

Authors:  Pablo Carbonell; María C Turpin; Daniel Torres-Moreno; Irene Molina-Martínez; José García-Solano; Miguel Perez-Guillermo; Pablo Conesa-Zamora
Journal:  J Mol Diagn       Date:  2011-06-25       Impact factor: 5.568

8.  Serrated Colorectal Lesions in Patients With Inflammatory Bowel Disease.

Authors:  Alyssa M Parian; Mark G Lazarev
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-01

9.  Novel anti-invasive properties of a Fascin1 inhibitor on colorectal cancer cells.

Authors:  Silvia Montoro-García; Begoña Alburquerque-González; Ángel Bernabé-García; Manuel Bernabé-García; Priscila Campioni Rodrigues; Helena den-Haan; Irene Luque; Francisco José Nicolás; Horacio Pérez-Sánchez; María Luisa Cayuela; Tuula Salo; Pablo Conesa-Zamora
Journal:  J Mol Med (Berl)       Date:  2020-01-29       Impact factor: 4.599

10.  Serrated lesions of the colorectum: review and recommendations from an expert panel.

Authors:  Douglas K Rex; Dennis J Ahnen; John A Baron; Kenneth P Batts; Carol A Burke; Randall W Burt; John R Goldblum; José G Guillem; Charles J Kahi; Matthew F Kalady; Michael J O'Brien; Robert D Odze; Shuji Ogino; Susan Parry; Dale C Snover; Emina Emilia Torlakovic; Paul E Wise; Joanne Young; James Church
Journal:  Am J Gastroenterol       Date:  2012-06-19       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.